Premium
A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice
Author(s) -
Andjelic Bosko,
Antic Darko,
Jakovic Ljubomir,
Todorovic Milena,
Bogdanovic Andrija,
Djurasinovic Vladislava,
Bila Jelena,
Mihaljevic Biljana
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12364
Subject(s) - abvd , medicine , stage (stratigraphy) , hodgkin lymphoma , clinical trial , multivariate analysis , disease , b symptoms , proportional hazards model , lymphoma , oncology , brentuximab vedotin , hodgkin's lymphoma , radiation therapy , surgery , chemotherapy , cyclophosphamide , vincristine , paleontology , biology
Based on the results of clinical trials, there is no global consensus on the optimal first‐line therapy for patients with advanced Hodgkin lymphoma (HL) with both ABVD and BEACOPP currently being used. However, the results of clinical trials are usually better than those in daily practice. We thus describe here our experience on 314 advanced classical HL patients treated with ABVD at the Clinical Center of Serbia and associated centers between 1997 and 2008. The median follow‐up for all patients was 91 months; the estimated 5‐yr event‐free survival was 62% and the 5‐yr overall survival (OS) 76%. Multivariate Cox regression analysis revealed that patients with IPS ≥ 3 and extranodal disease involving more than one site have a poorer outcome. The data presented here show on overall improvement in outcome as compared to more previous data and illustrate the problems of treating advanced stage HL outside the setting of a clinical trial.